Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2014-10-10
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies vismodegib and gemcitabine hydrochloride in treating
patients with advanced pancreatic cancer. Vismodegib may stop the growth of pancreatic cancer
by blocking blow flow to the tumor. Gemcitabine hydrochloride may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Giving vismodegib and
gemcitabine hydrochloride may kill more tumor cells.